NCT06361108View on ClinicalTrials.gov

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

December 20, 2025

Study Completion Date

June 30, 2026

Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
DRUG

YJ001 for Spray Use

Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)

DRUG

Placebo of YJ001 for Spray Use

Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water

Trial Locations (1)

78229

RECRUITING

Clinical Trials of Texas,LLC, Fredericksburg

All Listed Sponsors
lead

Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.

INDUSTRY